Form 4: 4D Molecular Therapeutics Director Acquires Stock Options

Jacob Chacko, a Director at 4D Molecular Therapeutics, Inc., was granted stock options for 50,000 shares.

Summary

• Jacob Chacko, a Director at 4D Molecular Therapeutics, Inc. (FDMT), acquired 50,000 stock options.
• The stock options have an exercise price of $9.42 per share.
• These options were granted on June 17, 2026, and are set to expire on June 16, 2036.
• The options vest over a period, with 1/3 vesting on June 17, 2027, and the remainder vesting monthly until June 17, 2029, contingent on continued service.
• Full vesting is also triggered upon a Change in Control event.
• The reporting person is Jacob Chacko, and the filing was made by one reporting person.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents standard director compensation and incentive alignment rather than a significant operational or financial update.

Positives

• Director Jacob Chacko has been granted a significant number of stock options (50,000), indicating potential future value and alignment with the company's performance.
• The stock options vest over time, incentivizing continued service and long-term commitment from the director.
• The grant of options at an exercise price of $9.42 suggests a belief in future stock appreciation above this level.

Negatives

• The filing only details the acquisition of options, not the current financial performance or operational updates of the company, which would provide a more comprehensive view.

Risks

• The value of the stock options is contingent on the future performance of 4D Molecular Therapeutics, Inc. and the market price of its common stock exceeding the exercise price of $9.42.
• Continued service is required for full vesting, meaning any departure before June 17, 2029, could result in forfeiture of unvested options.
• A Change in Control event, while triggering full vesting, could also represent a significant strategic shift or potential acquisition that may have its own associated risks and uncertainties.

Future Outlook

The future outlook for the stock options is positive, as they are designed to vest over time and provide potential financial benefit to the director if the company's stock price appreciates above the $9.42 exercise price.

Management Comments

• The stock option grant was automatically made pursuant to the terms of the Company's non-employee director compensation program.
• The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029.
• Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

Industry Context

StockSavvy.ai notes that the grant of stock options to directors is a common practice in the biotechnology and therapeutics sector, aligning executive incentives with shareholder value creation. The vesting schedule and change-in-control provisions are standard mechanisms to ensure director commitment and provide liquidity in potential M&A scenarios.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options aligns director interests with shareholders, potentially driving performance. However, dilution could occur if options are exercised.
• Employees: Standard compensation practice for directors, unlikely to have direct impact on other employees.
• Management: Reinforces the incentive structure for the board.
• Creditors: No direct impact.

Next Steps

• Director Jacob Chacko will continue to serve the company through the vesting periods.
• The company may experience a Change in Control event, which would trigger full vesting of these options.

Key Dates

Keywords

4D Molecular Therapeutics, FDMT, Form 4, Stock Options, Director Compensation, Beneficial Ownership, SEC Filing, Equity Award